Table 6.

Reported immunohistochemical property of breast mucinous carcinoma.

Study	Group	Number of Cases	Mean Age	ER	PgR	HER2	Ki-67	Ki-67 Threshold
Our study	Older (67–92 y/o)	21	81.7	100%	85.7%	0%	19%	5%
	Younger (28–55 y/o)	16	44.6	100%	81.3%	6.3%	37.5%	5%
Li et al. [1]	50–89 y/o	2730	n.a.	96%	83%	n.a.	n.a.	n.a.
	30–49 y/o	516	n.a.	91%	81%	n.a.	n.a.	n.a.
Di Saverio et al. [38]	25–85 y/o	11422	68.3	94.1%	81.5%	n.a.	n.a.	n.a.
de Andrade Natal et al. [6]	Type A	17	57.0	100%	52.9%	5.9%	0%	14%
	Type B	23	66.0	95.7%	73.9%	4.3%	21.7%	14%
Lacroix-Triki et al. [39]		35	n.a.	100%	85.7%	2.9%	8.6%	10%

ER, estrogen receptor; HER2, human epidermal growth receptor 2; PgR, progesterone receptor; n.a., not available.